Overexpression of the BRE (brain and reproductive organ-expressed) gene defines a distinct pediatric and adult acute myeloid leukemia (AML) subgroup. Here we identify a promoter enriched for active chromatin marks in BRE intron 4 causing strong biallelic expression of a previously unknown C-terminal BRE transcript. This transcript starts with BRE intron 4 sequences spliced to exon 5 and downstream sequences, and if translated might code for an N terminally truncated BRE protein. Remarkably, the new BRE transcript was highly expressed in over 50% of 11q23/KMT2A (lysine methyl transferase 2A)-rearranged and t(8;16)/KAT6A-CREBBP cases, while it was virtually absent from other AML subsets and normal tissues. In gene reporter assays, the leukemia-specific fusion protein KMT2A-MLLT3 transactivated the intragenic BRE promoter. Further epigenome analyses revealed 97 additional intragenic promoter marks frequently bound by KMT2A in AML with C-terminal BRE expression. The corresponding genes may be part of a context-dependent KMT2A-MLLT3-driven oncogenic program, because they were higher expressed in this AML subtype compared with other groups. C-terminal BRE might be an important contributor to this program because in a case with relapsed AML, we observed an ins(11;2) fusing CHORDC1 to BRE at the region where intragenic transcription starts in KMT2A-rearranged and KAT6A-CREBBP AML.
INTRODUCTION
Oncogene activation contributes to cancer onset and can be associated with treatment response. For instance, in acute myeloid leukemia (AML), high MECOM (MDS1-EVI1 complex) expression predicts poor outcome. 1 Chromosome 3 rearrangements juxtaposing a GATA2 super-enhancer to the MECOM locus cause MECOM overexpression, 2, 3 but MECOM overexpression also occurs in samples without chromosome 3 rearrangements. MECOM activation is caused by independent and recurrent chromosomal abnormalities, strongly suggesting its contribution to disease pathogenesis. Indeed, inhibition of MECOM expression resulted in cellular differentiation and growth inhibition in AML models.
2,4-6 MECOM overexpression lacking chromosome 3 abnormalities is recurrently found in AML with KMT2A (lysine methyl transferase 2A, MLL) translocations. MLLT3 (mixedlineage leukemia translocated to chromosome 3, AF9) is the most frequent fusion partner of KMT2A 7, 8 and KMT2A-MLLT3 may contribute to MECOM overexpression. 9 Since the majority of KMT2A-MLLT3 AML samples lack MECOM overexpression, 10,11 MECOM activation by KMT2A-MLLT3 may be context dependent. Earlier we reported that KMT2A-MLLT3 AML is characterized by mutually exclusive MECOM and BRE (brain and reproductive organ-expressed) overexpression. [10] [11] [12] These findings are relevant, because both pediatric and adult KMT2A-MLLT3 AML with BRE overexpression are associated with a favorable outcome. [10] [11] [12] BRE is relatively highly expressed in blood cells in general, suggesting an important function in hematopoiesis. BRE functions in BRCA-1 (breast cancer 1)-mediated DNA damage repair, BRISC (BRCC3 isopeptidase complex)-mediated deubiquitination and in protection from apoptosis and senescence. [13] [14] [15] [16] [17] [18] [19] [20] Its exact function in hematopoiesis remains to be determined. Importantly, it is currently unknown how BRE overexpression is caused in KMT2A-MLLT3 AML. Here, we generated RNAsequencing (RNA-seq) and chromatin immunoprecipitationsequencing (ChIP-seq) profiles from KMT2A-MLLT3 samples to obtain more insight into the mechanisms causing BRE overexpression. Cell culture, RNA isolation, cDNA synthesis, RT-(q)PCR, 5′-RACE and luciferase reporter assays Extensive methods for cell culture, RNA isolation, cDNA synthesis, real-time quantitative reverse transcription PCR (RT-(q)PCRs), 5′-Rapid Amplification of cDNA Ends (RACE) and luciferase reporter assays are described in the Supplementary Information.
ChIP, ChIP-seq and Illumina high-throughput sequencing Methods for H3K4me1, H3K4me3, H3K9me3, H3K27ac, H3K27me3, MECOM and KMT2A ChIP-seq/qPCR, RNA-seq and bioinformatic analyses are described in the Supplementary Information.
RESULTS
The epigenome of human KMT2A-MLLT3 AML To gain more insight into the epigenetic regulation of the MECOM and BRE loci in KMT2A-MLLT3 AML, we generated H3K4me1, H3K4me3 and H3K27ac ChIP-seq profiles from two primary KMT2A-MLLT3 AML samples (Figure 1a , one MECOM and one BRE overexpression (patients P1a and P2a; Table 1) ). This revealed 30 000 and~26 000 active promoters (H3K27ac/H3K4me3) as well as~40 500 and~46 000 active enhancers (H2K27ac/ H3K4me1) for P1a and P2a, respectively. The relative abundance and genomic distribution of active promoters and active enhancers was similar between P1a and P2a ( Figure 1b and Supplementary Figure 1a) . The common promoter and enhancer regions (465% of active promoters/enhancers) showed comparable average ChIP-seq signal intensities (Figure 1b) . In contrast, patient-specific active promoters and enhancers showed markedly higher average signals (Supplementary Figures 1B and C) . Remarkably, for H3K4me3/H3K27ac peaks, only 50% overlapped with annotated (RefSeq hg19) promoters, suggesting that KMT2A-MLLT3 samples might harbor many alternate transcription start sites. Thus, the epigenomes of MECOM-and BRE-overexpressing KMT2A-MLLT3 AML samples are comparable, and also contain unique features.
Deposition of active histone marks at annotated promoters in MECOM-overexpressing KMT2A-MLLT3 AML The sample with MECOM overexpression exhibited higher H3K4me3 signals than the sample with BRE overexpression at the two annotated MECOM promoter regions (Supplementary Figure 1D) . Additionally, H3K27ac was only detected at the H3K4me3 peaks in P1a, while no signal was found in P2a, which is in line with the low MECOM expression in P2a. These observations were subsequently confirmed in additional primary KMT2A-MLLT3 AML samples: by H3K4me3 ChIP-seq (n = 2 MECOM, n = 5 BRE overexpression), RNA-seq (n = 2 MECOM, n = 2 BRE overexpression) and a H3K27ac ChIP-seq profile (BRE overexpression, P4; Supplementary Figure 1E ). Taken together, these results show that MECOM overexpression is associated with increased deposition of active promoter marks at its two annotated promoters.
Intragenic promoter marks in BRE in KMT2A-MLLT3 AML Subsequently, the BRE locus was examined. No differences were detected in active enhancers around the BRE locus between the two initial KMT2A-MLLT3 AML samples (not shown). Interestingly, apart from enrichment on the annotated promoter, the sample with BRE overexpression contained intragenic active promoter marks (H3K4me3/H3K27ac) in BRE intron 4 that were absent in the sample with normal BRE/high MECOM expression (Figure 1c ).
These data were confirmed using ChIP-qPCRs on two KMT2A-MLLT3 cell lines and primary samples ( Figure 1d and Supplementary Figure 2A) . Analysis of all H3K4me3 ChIP-seq profiles revealed that 5/6 samples with BRE overexpression harbored an intragenic H3K4me3 peak in BRE (the peak in P6 was not called, likely due to the higher background levels), whereas none of the three samples with MECOM overexpression did ( Figure 1e and Supplementary Figures 2B and C). A second H3K27ac profile generated from a sample with BRE overexpression (P4) also showed a clear peak in the same region (not shown). These results show that the BRE intragenic active promoter marks were specific to KMT2A-MLLT3 samples with BRE overexpression.
Intragenic transcription activation causes high downstream BRE expression in KMT2A-MLLT3 AML Next, we investigated whether the intragenic BRE promoter was accompanied by the expression of a specific transcript. Indeed, RNA-seq from sample P2a (BRE overexpression) showed expression of intronic sequences adjacent to the active promoter marks, 3 kb upstream of exon 5 ( Figure 1c ). Downstream exons were expressed at a higher level compared with upstream exons. RNAseq and RT-qPCR in a larger cohort showed that exons upstream of the intragenic promoter were equally expressed in all KMT2A-MLLT3 samples (Figures 1f and g ). In contrast, downstream exons were five-to ninefold higher expressed in samples with BRE versus MECOM overexpression (Figure 1g ). The start of the new BRE transcript and fusion of intragenic reads to exon 5 as determined by RNA-seq ( Figure 1c ) was confirmed by 5′-RACE ( Figure 1h ) followed by Sanger sequencing. The new transcript contained ã 100 bp region within intron 4 (exon 1b) fused to exon 5. As several samples harbored a heterozygous single-nucleotide polymorphism within exon 1b, which was expressed, we could determine that alternate BRE expression was biallelic (not shown). Besides exons 1b and 5, the novel BRE transcript contained exons 6-12 explaining high expression of these downstream exons (Figures 1c and i and not shown). Importantly, the new transcript was not detected by 5′-RACE in three KMT2A-MLLT3 samples with MECOM overexpression. Instead, the expected transcript containing BRE exons 1-7 was amplified (~870 bp; Figure 1h ). Exon 5 codes for two methionines that potentially serve as translation start sites (Figure 1i ), which, if used, might result in the formation of a 138 or 154 amino-acid N terminally truncated BRE protein.
In conclusion, these results show that BRE overexpression in KMT2A-MLLT3 AML is caused by biallelic intragenic transcription activation from an alternate promoter in intron 4.
To study whether MECOM directly repressed the intragenic BRE promoter, we performed MECOM ChIP-qPCRs in a KMT2A-MLLT3 sample with high MECOM expression. The SPI1 enhancer region showed a clear enrichment for MECOM compared with control regions (Supplementary Figure 3A) . MECOM binding was also found on the normal BRE promoter, yet no enrichment was detected at the intragenic BRE promoter (Supplementary Figure 3A) . This suggests that MECOM does not directly repress the intragenic BRE promoter. Additionally, there is no indication for heterochromatin formation at the intragenic BRE promoter in samples with high MECOM expression, as the repressive promoter marks H3K27me3 and H3K9me3 were not detected (Supplementary Figure 3A) .
Novel BRE transcript in KMT2A-rearranged and KAT6A-CREBBP AML Our next goal was to study whether BRE intragenic transcription activation is unique to KMT2A-MLLT3 AML. We previously described samples with BRE overexpression without detectable rearrangements involving KMT2A. 12 To determine whether BRE overexpression in these samples is caused by intragenic transcription activation, we performed 5′-RACE on two such samples (patients 2184 and 6948 from Valk et al. 21 ). Identical fragments were identified in these samples as in KMT2A-MLLT3 AML with BRE overexpression (Figure 1h ), suggesting that expression of the new BRE transcript may occur independently of KMT2A rearrangements. We developed an RT-qPCR for detection of the new BRE transcript (Figure 1i ) to determine its prevalence in AML in general (Figure 1j ). The new BRE transcript was highly expressed in approximately half of the adult KMT2A-MLLT3 (13/24) as well as~70% and~50% of pediatric KMT2A-MLLT3 (13/19) and KMT2A-MLLT10 AMLs (7/15), respectively. As most KMT2A-rearranged AML samples have French-AmericanBritish M4 or M5 morphology, additional samples were screened for expression of the novel BRE transcript. Two of the 36 M4/M5 samples exhibited high expression of the new BRE transcript. Thus, morphological classification per se does not correlate with high expression of the new BRE transcript. The novel BRE transcript was only sporadically highly expressed in remaining AML samples (2/65) and was not found in other hematological malignancies (n = 16; Figure 1j ).
As BRE overexpression was previously detected in one KAT6A-CREBBP AML sample, 11 additional samples were screened for the new BRE transcript. Indeed, 3/7 adult and 10/13 pediatric KAT6A-CREBBP samples exhibited high new BRE transcript levels (Figure 1j ). The new BRE transcript was hardly detected in normal primary hematopoietic cells (Figure 1j and 20 different human tissues, not shown). Alternate BRE expression or the intragenic BRE H3K4me3/H3K27ac peak that we identified were not found in publicly available databases (not shown). We conclude that high expression of the new BRE transcript is largely confined to KMT2A-rearranged and KAT6A-CREBBP AML and is not present in healthy hematopoietic or non-hematopoietic cells. Red dots: (n = 168) fold change42; orange dots: (n = 23) fold change42, Bonferonni-adjusted P-valueo0.05; green dots: (n = 35) fold change44, Bonferonni-adjusted P-valueo0.01. AP, active promoter; int BRE prom, intragenic BRE promoter; Sig., significant; TF, transcription factor.
Genome-wide intragenic promoter marks in BRE-overexpressing KMT2A-MLLT3 AML To examine whether intragenic transcription activation is unique for BRE, we performed genome-wide analyses revealing~7000 H3K4me3/H3K27ac intragenic peaks that were specific for cases with BRE overexpression (Figure 2a ). To avoid false positives, we narrowed down the group of specific intragenic active promoters among others by including only those with a marked difference in the average H3K4me3 signal (Figure 2b and Supplementary  Figures 3B and C) . This analysis yielded intragenic active promoter marks that were unique to samples with BRE overexpression in 98 regions, residing in 90 genes (Figure 2b , Supplementary Figure 3C and Supplementary Genes with intragenic active promoter marks are activated in BREoverexpressing KMT2A-MLLT3 AML We analyzed the expression levels of the 90 genes with intragenic promoters in a large adult AML cohort. 24 This showed significantly higher expression of these genes in BRE-overexpressing samples as opposed to 11q23/KMT2A-rearranged MECOM-overexpressing samples (P = 0.015) and a trend towards higher expression compared with other genetically defined patient subsets (Figure 2c) . Remarkably, RNA-seq profiles described above indicated that only five (BRE, PAN3, SMYD3, MS4A7 and TGM5) of the 90 genes with intragenic promoters had ⩾ 2-fold increased [10] . (c) Schematic representation of the full-length and predicted new BRE proteins, CHORDC1 and the CHORDC1-BRE fusion protein (UEV: ubiquitin E2 variant, CHORD: cysteine-and histidine-rich, CS: interaction module named after CHORD-containing proteins and SGT1). Amino-acid numbers refer to proteins encoded by BRE transcript 3 (NM_199191) and CHORDC1 transcript 1 (NM_012124).
expression of downstream versus upstream exons relative to their intragenic active promoter mark (not shown). These data suggest that intragenic active promoter marks are found in actively transcribed genes, but do not necessarily cause transcription initiation at that position. Alternatively, intragenic transcription initiation might occur, but the expression or stability of downstream sequences may be so low that it does not result in a significant increase in read count.
The high expression of downstream SMYD3, PAN3 and TGM5 sequences in KMT2A-MLLT3 samples with versus without BRE overexpression was confirmed by RT-qPCR, but this was not found for KAT6A-CREBBP AML samples (Supplementary Figure 3D) . These results could imply that KAT6A-CREBBP and KMT2A-MLLT3 AML do not harbor a similar genome-wide intragenic active promoter signature.
KMT2A-MLLT3 transactivates the intragenic BRE promoter To determine whether KMT2A-MLLT3 contributes to intragenic BRE transcription, gene reporter assays were performed. Both the Hoxa7 promoter (positive control) and BRE fragments containing sequences from +17 to +410 bp relative to the novel transcription start site were transactivated in a dose-dependent manner by KMT2A-MLLT3, whereas a fragment containing the region −133 to +17 bp was not transactivated (Figure 2d ). To determine whether KMT2A or KMT2A-fusion proteins regulate the 98 intragenic active promoter marks, we analyzed three KMT2A ChIP-seq profiles, 25 one from a primary KMT2A-MLLT3 sample with BRE overexpression and two from the KMT2A-rearranged cell lines THP-1 and MV4-11 (Supplementary Figure 4A) . KMT2A signals were enriched at the 98 intragenic active promoter marks in all three samples (Figure 2e and Supplementary Figure 4B) . The level of KMT2A enrichment at the 98 intragenic promoter marks was similar to KMT2A enrichment in previously defined 25 KMT2A-fusion binding sites in THP-1 and MV4-11 cells (Supplementary Figures 4C and D) . These data suggest that KMT2A/KMT2A-fusion proteins bind to the intragenic active promoter marks to contribute to high expression of the respective genes.
AP-2, C2H2-Znf and ETS TF motif enrichment at intragenic promoter marks As only part of the KMT2A-MLLT3 AML samples have BRE overexpression, other factors besides KMT2A-MLLT3 might be involved in expression of the new BRE transcript. To identify candidates that may bind intragenic active promoter marks, we performed transcription factor (TF) motif analysis. This showed enrichment of motifs for AP-2, C2H2-Znf and ETS TF families (Figure 2f ). RNA-seq data from two BRE-and two MECOMoverexpressing samples revealed significant differential expression of 58 TFs belonging to these families (Figure 2g ). Only two TFs were higher expressed in BRE compared with MECOMoverexpressing samples (PLAG1 and ZNF595). Possibly, PLAG1 and ZNF595 are involved in enhancing transcription of the 90 genes with intragenic promoters.
A novel ins(11;2) fuses CHORDC1 to BRE exon 5 As described above, the BRE gene is actively transcribed from an intragenic promoter preceding exon 5. To find other changes in BRE in AML, we screened an RNA-seq library (32 paired diagnosisrelapse samples) for alterations in the BRE gene. Interestingly, an in-frame fusion transcript between CHORDC1 exon 5 (chromosome 11) and BRE exon 5 (chromosome 2) was found in a relapsed AML case. This fusion was confirmed by RT-PCR followed by Sanger sequencing, and an insertion of chromosome 2 into 11 was confirmed by karyotyping (Figures 3a and b) . Heterozygous Chordc1 (Morgana) inactivation in mice results in spontaneous atypical chronic myeloid leukemia. 26 The CHORDC1 fusion to BRE exon 5 is remarkable because the alternate BRE transcript starts with exon 1b also fused to exon 5. This means that if the CHORDC1-BRE and alternate BRE transcripts would be translated, they might contain a similar C-terminal part of the BRE protein (Figure 3c ). BRE and CHORDC1 were equally expressed in the diagnosis and relapse samples (stranded RNA-seq data, not shown). The CHORDC1-BRE fusion was not detected at diagnosis nor in 200 randomly selected de novo AML cases (not shown), indicating that this fusion is rare in de novo AML and may be associated with relapsed AML. Thus, leukemia-specific expression of the C terminus of BRE may be caused by intragenic transcription activation or chromosomal insertions.
DISCUSSION
Here, we report abnormal expression of C-terminal BRE sequences specific for AML, caused by distinct, non-random events, by a chromosomal insertion and by an intragenic transcription initiation in 11q23/KMT2A-rearranged and t(8;16)/KAT6A-CREBBP AML. The intragenic transcriptional activation cannot be explained by recurrent chromosomal abnormalities affecting the BRE locus itself, because the alternate transcript was expressed from both alleles. Instead, the oncofusion protein KMT2A-MLLT3 could be involved in intragenic BRE activation. In KMT2A-MLLT3 AML harboring the intragenic BRE promoter, we observed active intragenic promoter marks in 89 additional genes. KMT2A/ KMT2A-fusion protein enrichment was observed at these promoter marks and the corresponding genes were overexpressed in KMT2A-rearranged AML with high BRE expression. Moreover, KMT2A-MLLT3 activated the intragenic BRE promoter in reporter assays. These findings suggest that KMT2A-MLLT3 contributes to alternate transcription initiation in BRE. It should, however, be noted that especially in adult AML a significant number of samples with these two fusion oncoproteins lack high expression of the new BRE transcript. Thus, intragenic BRE activation may be dependent on additional factors. Motif analyses of KMT2A-MLLT3 AML showed an overrepresentation of AP-2, C2H2-Znf, and ETS TF binding sites at intragenic promoter marks with C2H2-Znf TFs PLAG1 and ZNF595 being highly expressed in BRE overexpression cases. It would be interesting to test the contribution of especially PLAG1 to alternate BRE expression, as PLAG1 has been implicated in AML development.
27,28
Earlier we reported that patients with BRE overexpression have a superior outcome compared with MECOM-overexpressing patients. The unique 5′ end of the novel BRE transcript allows for reliable detection by RT-qPCR enabling an optimal recognition of both subtypes. Importantly, the association of alternate BRE expression with good clinical outcome appears to be restricted to KMT2A-rearranged AML, as patients with t(8;16)/KAT6A-CREBBP have a very dismal outcome in general.
KMT2A-MLLT3 and KAT6A-CREBBP may contribute to AML pathogenesis by altering gene expression. [29] [30] [31] [32] [33] [34] We observed that the genes with active intragenic promoter marks were bound by KMT2A/KMT2A-fusion proteins, and, indeed, the respective genes showed highest expression compared with other AML subtypes. These genes might represent a newly identified oncogenic program. It is tempting to speculate that alternate BRE contributes to this oncogenic program for various reasons. Abnormal BRE expression is exclusively observed in AML and caused by distinct mechanisms. The novel BRE transcript contains two putative translation start sites in exon 5, which if used might possibly lead to N terminally truncated BRE isoforms. The in-frame CHORDC1-BRE fusion includes a similar C-terminal part of BRE and Chordc1 functions as a tumor suppressor in mice. 26 BRE is required for proper function of the BRCA-1-A and BRISC complexes, which are involved in DNA repair and cell cycle regulation. 14, [17] [18] [19] [20] 35, 36 Another important constituent of these complexes is BRCC3. Mutations in BRCC3 and other components of these two complexes have recently been observed in myeloid malignancies, including AML. 37 BRE overexpression is also found in other malignancies and correlates with higher grade tumors. 38, 39 In addition to AML, BRE has prognostic impact in breast cancer and a translocation including downstream BRE sequences has been observed in adrenocortical carcinoma. 40, 41 We conclude that it will be interesting to determine whether leukemia-specific alternate BRE transcripts are translated into protein and contribute to disease pathogenesis.
